| Project/Area Number |
20591518
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
YAMAMOTO Kiyohito Nagoya University, 医学部附属病院, 講師 (10298359)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOMORI Kimihiro 名古屋大学, 大学院・医学系研究科, 教授 (40225587)
KOBAYASHI Masayoshi 名古屋大学, 医学部附属病院, 助教 (60329381)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2009: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2008: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | Rho-Kinase / ステント / 内膜肥厚 |
|---|
| Research Abstract |
Background : Rho kinase plays an important role in vascular smooth muscle cell (VSMC) contraction and other cellular functions, such as proliferation, migration, and apoptosis. We examined whether long-term inhibition of Rho kinase suppresses stent-induced hyperplasia in hypercholesterolemic rabbits.
Experiment I :
Methods : Male rabbits were fed a 1.0% cholesterol diet for 4 weeks before stent implantation. Then, randomly divided into two groups and received cholesterol chow (control group) or a special chow containing fasudil.
Results : The intimal thickening of the fasudil group was comparable with the control group. There was not significant difference between the two groups.
Experiment II :
Background : We investigated whether Ezetimibe, which reduce the high-cholestetrol level, inhibited the intimal hyperplasia induced by vein graft and additionally, relationship between the inhibited effect on Rho-kinase.
Results : We demonstrated that oral administration of Ezetimibe to normocholesterolemic rabbits inhibited intimal hyperplasia of carotid interposition-reversed jugular vein grafts 4 weeks after implantation.
|
